Michael Feld sold $14k of BDX
EVP, Chief Revenue Officer at BECTON DICKINSON & CO. 76 shares at an average of $183.70, traded Sep 28, 2026, filed Sep 29, 2026.
Score components
- +15RoleOfficer
- 0Trade size$14k at market
- 0Share of holdings soldSold 0.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-063882, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | SOpen-market sale Common Stock10b5-1 | -76 | $183.70 | $14k | 19,644 | 13 d ago |
Related signals
Other insiders at BECTON DICKINSON & CO and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $10k 58 shares | -1% | |
| 26Weak | BDXsell BECTON DICKINSON & CO | Claire Fraser director | $172k 917 shares | -4% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $11k 57 shares | -1% | |
| 54Moderate | BDXbuy BECTON DICKINSON & CO | Gregory Hayes director | $1.0M 5,250 shares | +660% | |
| 34Weak | BECTON DICKINSON & CO | Claire Fraser director | $166k 863 shares | -4% | |
| 0Weak | BECTON DICKINSON & CO | Michael David Garrison EVP & President, Medical | $214k 1,185 shares | -20% | |
| 12Weak | BECTON DICKINSON & CO | David Shan EVP and Chief ISC Officer | $200k 1,166 shares | -20% | |
| 5Weak | BECTON DICKINSON & CO | Michael David Garrison EVP & President, Medical | $94k 479 shares | -9% | |
| 5Weak | BECTON DICKINSON & CO | Richard Byrd EVP & President Interventional | $106k 459 shares | -6% | |
| 17Weak | BECTON DICKINSON & CO | Richard Byrd EVP & President Interventional | $436k 1,940 shares | -21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.